BACKGROUND & AIMS: Malnutrition is variably encountered in adult patients with Crohn's disease. We evaluated the nutritional status at the beginning and during Infliximab treatment in patients with Crohn's disease. METHODS: Patients with moderate/severe flares of disease treated with Infliximab for induction and maintenance of remission were included in a prospective observational study. Body Mass Index and Nutritional Risk Index were calculated in each patient at 0, 6 weeks and than every 8 weeks for one year. RESULTS: From 30 patients treated with Infliximab 59.3% had low BMI, 35.7% being undernourished. The severity of Crohn's disease did not correlate with low BMI but did correlate with Nutritional Risk Index (p = 0.001). In all patients that responded to Infliximab treatment progressive weight gain was observed, all but one patient reaching normal BMI after one year. Mean weight gain was significantly more elevated (p = 0.001) and time needed to reach normal BMI was longer in the undernutrition group (p = 0.01). Clinical remission was the principal factor associated with weight gain (p = 0.001), while there was no influence of endoscopic remission on nutritional status. CONCLUSIONS: In patients with moderate/severe forms of Crohn's disease malnutrition is frequently encountered. Induction and maintenance treatment with Infliximab determines weight gain and corrects malnutrition in all patients with clinical remission.
BACKGROUND & AIMS:Malnutrition is variably encountered in adult patients with Crohn's disease. We evaluated the nutritional status at the beginning and during Infliximab treatment in patients with Crohn's disease. METHODS:Patients with moderate/severe flares of disease treated with Infliximab for induction and maintenance of remission were included in a prospective observational study. Body Mass Index and Nutritional Risk Index were calculated in each patient at 0, 6 weeks and than every 8 weeks for one year. RESULTS: From 30 patients treated with Infliximab 59.3% had low BMI, 35.7% being undernourished. The severity of Crohn's disease did not correlate with low BMI but did correlate with Nutritional Risk Index (p = 0.001). In all patients that responded to Infliximab treatment progressive weight gain was observed, all but one patient reaching normal BMI after one year. Mean weight gain was significantly more elevated (p = 0.001) and time needed to reach normal BMI was longer in the undernutrition group (p = 0.01). Clinical remission was the principal factor associated with weight gain (p = 0.001), while there was no influence of endoscopic remission on nutritional status. CONCLUSIONS: In patients with moderate/severe forms of Crohn's disease malnutrition is frequently encountered. Induction and maintenance treatment with Infliximab determines weight gain and corrects malnutrition in all patients with clinical remission.
Authors: Márcia Soares-Mota; Tianny A Silva; Luanda M Gomes; Marco A S Pinto; Laura M C Mendonça; Maria Lúcia F Farias; Tiago Nunes; Andrea Ramalho; Cyrla Zaltman Journal: World J Gastroenterol Date: 2015-02-07 Impact factor: 5.742
Authors: Valérie Marcil; Emile Levy; Devendra Amre; Alain Bitton; Ana Maria Guilhon de Araújo Sant'Anna; Andrew Szilagy; Daniel Sinnett; Ernest G Seidman Journal: Inflamm Bowel Dis Date: 2019-07-17 Impact factor: 5.325
Authors: Fares Ayoub; Amir Y Kamel; Ahmed Ouni; Naueen Chaudhry; Yan Ader; Sanda Tan; Atif Iqbal; Ellen M Zimmermann; Sarah C Glover Journal: Gastroenterol Rep (Oxf) Date: 2018-09-04
Authors: Jan Bilski; Bartosz Brzozowski; Agnieszka Mazur-Bialy; Zbigniew Sliwowski; Tomasz Brzozowski Journal: Biomed Res Int Date: 2014-04-30 Impact factor: 3.411
Authors: Radan Keil; Martin Wasserbauer; Zdena Zádorová; Jan Hajer; Pavel Drastich; Pavel Wohl; Marek Beneš; Martina Bojková; Pavel Svoboda; Michal Konečný; Přemysl Falt; Tomáš Vaňásek; Martin Pešta; František Pešek; Luděk Bouchner; Jana Koželuhová; Aleš Novotný; Lucie Bartůsková; Julius Špičák Journal: Scand J Gastroenterol Date: 2016-03-22 Impact factor: 2.423